| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,897,741 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schlesinger Sarah J. |
Director |
• • – |
2014-08-12 |
4 |
AB |
$5.52 |
$7,176 |
I/I |
1,300 |
1,300 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$25,421 |
D/D |
(4,564) |
280,960 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,000 |
285,524 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$86,647 |
D/D |
(15,556) |
1,122,621 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,800 |
1,138,177 |
|
- |
|
| Berstein David L |
SVP, GC and Chief IP Officer |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$14,527 |
D/D |
(2,608) |
236,034 |
|
- |
|
| Berstein David L |
SVP, GC and Chief IP Officer |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
238,642 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$14,527 |
D/D |
(2,608) |
95,299 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
97,907 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$25,421 |
D/D |
(4,564) |
413,565 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,000 |
418,129 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$14,527 |
D/D |
(2,608) |
153,455 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
156,063 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs and HR |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$14,527 |
D/D |
(2,608) |
91,374 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs and HR |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
93,982 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$5,085 |
D/D |
(913) |
35,450 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2014-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
36,363 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs and HR |
• • – |
2014-06-02 |
4 |
AS |
$6.90 |
$25,611 |
D/D |
(3,713) |
84,461 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs and HR |
• • – |
2014-04-02 |
4 |
AS |
$8.21 |
$34,907 |
D/D |
(4,250) |
88,174 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2014-04-02 |
4 |
AS |
$8.21 |
$27,916 |
D/D |
(3,400) |
104,296 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2014-04-02 |
4 |
AS |
$8.22 |
$19,720 |
D/D |
(2,400) |
148,063 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2014-04-02 |
4 |
AS |
$8.21 |
$53,337 |
D/D |
(6,500) |
403,028 |
|
- |
|
| Berstein David L |
SVP, GC and Chief IP Officer |
• • – |
2014-04-02 |
4 |
AS |
$8.22 |
$19,718 |
D/D |
(2,400) |
230,642 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs and HR |
• • – |
2014-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
92,424 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2014-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
107,696 |
|
- |
|
703 Records found
|
|
Page 9 of 29 |
|
|
